Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASCADE: vadastuximab talirine plus azacitidine or decitabine in newly diagnosed older adults with acute myeloid leukemia
MOH_2017-03-26_000276Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) comparing 33A + HMA with Placebo + HMA (2 arms). Primary endpoint: Overall survival. Started Aug 2016; status: completed.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2017-03-26_000276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-26_000276.